PT - JOURNAL ARTICLE AU - Jagannathan, Prasanna AU - Andrews, Jason R. AU - Bonilla, Hector AU - Hedlin, Haley AU - Jacobson, Karen B. AU - Balasubramanian, Vidhya AU - Purington, Natasha AU - Kamble, Savita AU - de Vries, Christiaan R. AU - Quintero, Orlando AU - Feng, Kent AU - Ley, Catherine AU - Winslow, Dean AU - Newberry, Jennifer AU - Edwards, Karlie AU - Hislop, Colin AU - Choong, Ingrid AU - Maldonado, Yvonne AU - Glenn, Jeffrey AU - Bhatt, Ami AU - Blish, Catherine AU - Wang, Taia AU - Khosla, Chaitan AU - Pinsky, Benjamin A. AU - Desai, Manisha AU - Parsonnet, Julie AU - Singh, Upinder TI - Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial AID - 10.1101/2020.11.18.20234161 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.18.20234161 4099 - http://medrxiv.org/content/early/2020/11/23/2020.11.18.20234161.short 4100 - http://medrxiv.org/content/early/2020/11/23/2020.11.18.20234161.full AB - Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized placebo-controlled trial in 120 patients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint, NCT04331899). In both the 60 patients receiving Lambda and the 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively (HR 0.94; 95% CI 0.64 to 1.39). At enrollment; 41% of subjects were SARS-CoV-2 IgG seropositive; compared to placebo, lambda tended to delay shedding cessation in seronegatives (aHR 0.66, 95% CI 0.39-1.10) and to hasten shedding cessation in seropositives (aHR 1.58, 95% CI 0.88-2.86; p for interaction = 0.03). Liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.Competing Interest StatementColin Hislop and Ingrid Choong are scientists at Eiger BioPharmaceuticals, Inc., which provided the Interferon Lambda used for this study. Jeffrey Glenn serves on the board of Eiger BioPharmaceuticals, Inc. Colin Hislop and Ingrid Choong own stock and options of Eiger BioPharmaceuticals, Inc. Jeffrey Glenn has an equity interest in Eiger BioPharmaceuticals, Inc. Jeffrey Glenn and Ingrid Choong are inventors on a pending patent application relating to the use of interferon lambda for coronavirus. Eiger BioPharmaceuticals played no role in study design, conduct of the study, or analysis of the data.Clinical TrialClinicalTrials.gov NCT04331899Funding StatementThe study was funded by anonymous donors to Stanford University, and Lambda provided by Eiger BioPharmaceuticals. The funders had no role in data collection and analysis or the decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Stanford University Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available at Stanford Digital Repository, lane.stanford.edu, at time of final publication.